(Hydroxymethyl)acylfulvene: An illudin derivative with superior antitumor properties

Journal of Natural Products

Volumn 59, Issue 9, 1996, Pages 896-899

  McMorris, Trevor C ^a   Kelner, Michael J ^a   Wang, Wen ^a   Yu, Jian ^a   Estes, Leita A ^a   Taetle, Raymond ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 HYDROXYMETHYLACYLFULVENE; ANTINEOPLASTIC AGENT; ILLUDIN S; PARAFORMALDEHYDE; SESQUITERPENE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN HL 60; DRUG ISOLATION; DRUG STRUCTURE; FUNGUS; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BASIDIOMYCOTA; CHROMATOGRAPHY, THIN LAYER; CRYSTALLOGRAPHY, X-RAY; DRUG SCREENING ASSAYS, ANTITUMOR; HL-60 CELLS; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; SESQUITERPENES;

FUNGI;

EID: 0029834306     PISSN: 01633864     EISSN: None     Source Type: Journal    
DOI: 10.1021/np960450y     Document Type: Article

References (15)

1. Beck, W. T.; Cass, C. E.; Houghton, P. J. Cancer Medicine, 3rd ed.; Lea and Febiger: Philadelphia, 1993; Vol. 1, p 782.
2. Ammirati, J. F.; Traquair, J. A.; Horgen, P. A. Poisonous Mushrooms of the Northern United States and Canada; University of Minnesota Press: Minneapolis, 1985; p 290.
3. McMorris, T. C.; Anchel, M. J. Am. Chem. Soc. 1965, 87, 1594-1600.
4. Kelner, M. J.; McMorris, T. C; Taetle, R. J. Natl. Cancer Inst. 1990, 82, 1562-1565.
5. McMorris, T. C.; Kelner, M. J.; Wang, W.; Estes, L. A.; Montoya, M. A.; Taetle, R. J. Org. Chem. 1992, 57, 6876-6883.
6. Kelner, M. J.; McMorris, T. C.; Estes, L.; Starr, R.; Samson, K.; Varki, N.; Taetle, R. Anticancer Res. 1995, 15, 867-872.
7. Kelner, M. J.; McMorris, T. C.; Taetle, R. Anticancer Res. 1995, 15, 873-878.
8. Kelner, M. J.; McMorris, T. C.; Estes, L. A.; Montoya, M. A.; Starr, R.; Samson, K.; Taetle, R. Cancer Res. 1995, 55, 4936-4940.
9. McMorris, T. C.; Kelner, M. J.; Wang, W.; Diaz, M. A.; Estes, L. A.; Taetle, R. Experientia 1996, 52, 75-80.
10. McMorris, T. C.; Kelner, M. J.; Wang, W.; Moon, S.; Taetle, R. Chem. Res. Toxicol. 1990, 3, 574-579.
11. Tanaka, K.; Inoue, T.; Kadota, S.; Kikuchi, T. Xenobiotica 1992, 22, 33-39.
12. Kelner, M. J.; McMorris, T. C.; Estes, L. A.; Wang, W.; Samson, K. M.; Taetle, R. Investigational New Drugs 1996 (in press).
13. Kelner, M. J.; McMorris, T. C.; Estes, L. A.; Rutherford, M.; Montoya, M.; Goldstein, J.; Samson, K.; Starr, R.; Taetle, R. Biochem. Pharmacol. 1994, 48, 403-409,
14. Woynarowski, J. M.; Napier, C.; Koester, S.; Chen, S. F.; Troyer, D. S.; Chapman, W.; MacDonald, J. Presented at the 9th NCI-EORTC Symposium on New Drugs in Cancer Chemotherapy, Amsterdam, March 12-15, 1996; abstract no. 257.
15. Unpublished data provided by MGI Pharma Inc., Minneapolis. This company has been licensed by the University of California to develop illudin analogues for treating tumors. U.S. Patents 5,439,936 and 5,439,942 on these compounds were issued to the University of California, Aug 8, 1995.